Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials
Authors:
- 1 March 2020
- journal article
- research article
- Published by Elsevier in The Lancet Haematology
- Vol. 7 (3) , e209-e217
Abstract
No abstract availableKeywords
Funding Information
- Roche
- Janssen Pharmaceutica
- Bristol-Myers Squibb
This publication has 21 references indexed in Scilit:
- Clinical Development of SiltuximabCurrent Oncology Reports, 2015
- Interleukin-6 as a Therapeutic TargetClinical Cancer Research, 2015
- Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of SiltuximabThe Patient - Patient-Centered Outcomes Research, 2015
- The Multicentric Castleman's Disease (Mcd) -Symptom Scale (Mcd-Ss): Development and Validation of A Patient-Reported Outcome (Pro) Measure for An Ultra-Orphan DiseaseValue in Health, 2014
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2014
- Siltuximab: First Global ApprovalDrugs, 2014
- HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapyBlood, 2014
- A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman DiseaseClinical Cancer Research, 2013
- Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell CarcinomaClinical Cancer Research, 2010
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005